Search alternatives:
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
cause decreased » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
mean decrease » a decrease (Expand Search)
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
cause decreased » caused decreased (Expand Search), use decreased (Expand Search), causes increased (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
mean decrease » a decrease (Expand Search)
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
Baseline Characteristics of Study Participants Stratified by Sleep Duration Categories.
Published 2025Subjects: -
133
Incidence of New-Onset Cardiovascular Disease in 2018 Follow-up by Sleep Duration Groups.
Published 2025Subjects: -
134
Subgroup Analysis of Sleep Duration and Cardiovascular Disease Risk in Type 2 Diabetes Patients.
Published 2025Subjects: -
135
-
136
-
137
-
138
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
139
-
140